Acadia Pharmaceuticals ACAD Operating Lease Liabilities (Current)

Operating Lease Liabilities (Current) at other companies

Neurocrine BiosciencesNBIX

$57.3M+25.7%

MapLight Therapeutics, Inc.MPLT

$920K—

Taysha Gene Therapies, Inc.TSHA

$996K-24.9%

Zevra Therapeutics, Inc.ZVRA

$626K+19.2%

LBR

LB Pharmaceuticals IncLBRX

$730K—

Rapport Therapeutics, Inc.RAPP

$2.47M+40.6%

FAQ

What is Acadia Pharmaceuticals's operating lease liabilities (current)?

Acadia Pharmaceuticals (ACAD) reported operating lease liabilities (current) of $14.31M in Q2 2026.

How has Acadia Pharmaceuticals's operating lease liabilities (current) changed year-over-year?

Acadia Pharmaceuticals's operating lease liabilities (current) increased by 22.4% year-over-year, from $11.69M to $14.31M.

What is the long-term trend for Acadia Pharmaceuticals's operating lease liabilities (current)?

Over 5 years (2020 to 2025), Acadia Pharmaceuticals's operating lease liabilities (current) has grown at a 18.0% compound annual growth rate (CAGR), from $5.09M to $11.63M.

What does operating lease liabilities (current) mean?

The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.